UY32745A - Nuevos conjugados de criptoficinas, su preparacion y su aplicacion terapeutica - Google Patents

Nuevos conjugados de criptoficinas, su preparacion y su aplicacion terapeutica

Info

Publication number
UY32745A
UY32745A UY0001032745A UY32745A UY32745A UY 32745 A UY32745 A UY 32745A UY 0001032745 A UY0001032745 A UY 0001032745A UY 32745 A UY32745 A UY 32745A UY 32745 A UY32745 A UY 32745A
Authority
UY
Uruguay
Prior art keywords
therapeutic application
cryptoficin
conjugates
preparation
new
Prior art date
Application number
UY0001032745A
Other languages
English (en)
Inventor
Alain Commercon
Herve Bouchard
Brun Marie Priscille
Jidong Ahang
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41611078&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY32745(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of UY32745A publication Critical patent/UY32745A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C07D273/08—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and more than one oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D245/00—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms
    • C07D245/04—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D245/06—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems condensed with one six-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invención se refiere a un agente de selección de la diana al que está unido al menos un derivado de criptoficina de la fórmula (I) en la que los radicales y sustituyentes son tales como se especifican en la Memoria y en las Reivindicaciones estando unidos el agente de selección de la diana y el derivado de criptoficina de forma covalente, situándose la unión en posición orto (o), meta (m) o para (p) del núcleo fenilo portador del motivo CR1. También se divulgan las composiciones que los contienen y a su aplicación terapéutica, especialmente como anticancerosos.
UY0001032745A 2009-06-29 2010-06-29 Nuevos conjugados de criptoficinas, su preparacion y su aplicacion terapeutica UY32745A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0903170A FR2947269B1 (fr) 2009-06-29 2009-06-29 Nouveaux composes anticancereux
FR0905651A FR2947271B1 (fr) 2009-06-29 2009-11-25 Nouveaux composes anticancereux

Publications (1)

Publication Number Publication Date
UY32745A true UY32745A (es) 2011-01-31

Family

ID=41611078

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001032745A UY32745A (es) 2009-06-29 2010-06-29 Nuevos conjugados de criptoficinas, su preparacion y su aplicacion terapeutica

Country Status (30)

Country Link
US (1) US8952147B2 (es)
EP (1) EP2448929A1 (es)
JP (1) JP5746692B2 (es)
KR (1) KR101770584B1 (es)
CN (1) CN102482238B (es)
AR (1) AR078131A1 (es)
BR (1) BRPI1015131A2 (es)
CA (1) CA2766762C (es)
CL (1) CL2011003229A1 (es)
CO (1) CO6430462A2 (es)
CR (1) CR20110670A (es)
DO (1) DOP2011000376A (es)
EA (1) EA024627B1 (es)
EC (1) ECSP11011553A (es)
FR (2) FR2947269B1 (es)
HN (1) HN2011003414A (es)
IL (1) IL217208A (es)
MA (1) MA33465B1 (es)
MX (1) MX2011013764A (es)
MY (1) MY156684A (es)
NI (1) NI201100219A (es)
NZ (1) NZ597136A (es)
PE (1) PE20121031A1 (es)
SG (2) SG10201607595WA (es)
SV (1) SV2011004086A (es)
TN (1) TN2011000636A1 (es)
TW (1) TW201110986A (es)
UY (1) UY32745A (es)
WO (1) WO2011001052A1 (es)
ZA (1) ZA201109537B (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2533992T3 (es) 2005-08-24 2015-04-16 Immunogen, Inc. Procedimiento para preparar conjugados de anticuerpo maitansinoide
KR102444399B1 (ko) 2009-06-03 2022-09-16 이뮤노젠 아이엔씨 메이탄시노이드의 제조방법
JP5677425B2 (ja) 2009-06-29 2015-02-25 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ Ｐｉ３ｋ阻害剤としてのピリミジノン
WO2011075643A1 (en) 2009-12-18 2011-06-23 Incyte Corporation Substituted heteroaryl fused derivatives as pi3k inhibitors
CA2796311A1 (en) 2010-04-14 2011-10-20 Incyte Corporation Fused derivatives as pi3k.delta. inhibitors
WO2011163195A1 (en) 2010-06-21 2011-12-29 Incyte Corporation Fused pyrrole derivatives as pi3k inhibitors
EP2655374B1 (en) 2010-12-20 2019-10-23 Incyte Holdings Corporation N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
WO2012125629A1 (en) 2011-03-14 2012-09-20 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
UA116524C2 (uk) 2011-03-29 2018-04-10 Іммуноджен, Інк. Спосіб одержання кон'югата антитіло-майтансиноїд
KR102507287B1 (ko) 2011-09-02 2023-03-07 인사이트 홀딩스 코포레이션 Ｐｉ３ｋ 억제제로서 헤테로시클릴아민
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
RU2661083C2 (ru) 2012-10-04 2018-07-11 Иммуноджен, Инк. Использование пвдф-мембраны для очистки конъюгатов клеточно-связывающий агент - цитотоксический агент
ES2756526T3 (es) 2013-07-11 2020-04-27 Novartis Ag Modificaciones de proteínas quimioenzimáticas específicas para lisina utilizando transglutaminasa microbiana
US10077277B2 (en) 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
TWI697493B (zh) * 2014-09-03 2020-07-01 美商免疫原公司 細胞毒性苯并二氮呯衍生物
GB201416960D0 (en) 2014-09-25 2014-11-12 Antikor Biopharma Ltd Biological materials and uses thereof
PE20180129A1 (es) 2015-02-27 2018-01-18 Incyte Corp Sales de inhibidor de pi3k y procesos de preparacion
EP3069734A1 (en) 2015-03-17 2016-09-21 Exiris S.r.l. Cryptophycin-based antibody-drug conjugates with novel self-immolative linkers
US9988401B2 (en) 2015-05-11 2018-06-05 Incyte Corporation Crystalline forms of a PI3K inhibitor
US9732097B2 (en) 2015-05-11 2017-08-15 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
TWI660741B (zh) 2015-11-03 2019-06-01 財團法人工業技術研究院 抗體藥物複合物及其製造方法
TWI714661B (zh) * 2015-11-05 2021-01-01 法商賽諾菲公司 新穎念珠藻素化合物及接合物、其製備與其治療用途
WO2017136769A1 (en) * 2016-02-04 2017-08-10 Eisai R&D Management Co., Ltd. Peptide drug conjugates
WO2018178277A1 (en) 2017-03-29 2018-10-04 Avicenna Oncology Gmbh New targeted cytotoxic isocombretaquinoline derivatives and conjugates thereof
MX2019013421A (es) * 2017-05-10 2020-02-05 Sanofi Sa Enlazadores peptidicos y conjugados de criptoficina, utiles en la terapia, y su preparacion.
CA3072399A1 (en) 2017-08-09 2019-02-14 Helmholtz-Zentrum Fur Infektionsforschung Gmbh New targeted cytotoxic ratjadone derivatives and conjugates thereof
AU2018389100A1 (en) * 2017-12-22 2020-07-09 Cornell University 18F-labeled peptide ligands useful in PET and Cerenkov luminescene imaging
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11911484B2 (en) 2018-08-02 2024-02-27 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US20210308273A1 (en) 2018-08-02 2021-10-07 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
KR20210081324A (ko) 2018-08-02 2021-07-01 다인 세라퓨틱스, 인크. 근육 표적화 복합체 및 안면견갑상완 근육 이영양증을 치료하기 위한 그의 용도
FR3085952B1 (fr) 2018-09-17 2020-10-30 Centre Nat Rech Scient Conjugue anticorps-medicament comprenant des derives de quinoline
EP4038085A1 (en) 2019-09-30 2022-08-10 The Regents of The University of Michigan Biocatalytic synthesis of cryptophycin anticancer agents
EP4046996A1 (en) 2021-02-19 2022-08-24 Universität Bielefeld Cryptophycin compounds and conjugates thereof
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
US11672872B2 (en) 2021-07-09 2023-06-13 Dyne Therapeutics, Inc. Anti-transferrin receptor antibody and uses thereof
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11633498B2 (en) 2021-07-09 2023-04-25 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
WO2023057564A1 (en) 2021-10-07 2023-04-13 Sanofi IMIDAZO[4,5-c]QUINOLINE-4-AMINE COMPOUNDS AND CONJUGATES THEREOF, THEIR PREPARATION, AND THEIR THERAPEUTIC APPLICATIONS
US11931421B2 (en) 2022-04-15 2024-03-19 Dyne Therapeutics, Inc. Muscle targeting complexes and formulations for treating myotonic dystrophy

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2719170A (en) 1954-07-28 1955-09-27 Du Pont Alkyl omega-carboxyalkyl disulfides and their lower alkyl esters
US4981979A (en) 1987-09-10 1991-01-01 Neorx Corporation Immunoconjugates joined by thioether bonds having reduced toxicity and improved selectivity
AU645745B2 (en) 1988-12-22 1994-01-27 Xoma Corporation Hindered linking agents and methods
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2056039A1 (en) 1991-01-22 1992-07-23 Philip L. Fuchs Carbacyclin analogs
PL185949B1 (pl) 1995-03-07 2003-09-30 Univ Hawaii Nowe związki kryptoficynowe, sposób wytwarzania nowych związków kryptoficynowych, zawierająca je kompozycja farmaceutyczna i ich zastosowanie
EP0934065B1 (en) * 1996-08-30 2006-06-07 University Of Hawaii Novel cryptophycin derivatives as anti-neoplastic agents
CA2347246A1 (en) 1998-10-16 2000-04-27 James Abraham Aikins Stereoselective process for producing cryptophycins
AU1930100A (en) 1998-12-07 2000-06-26 Eli Lilly And Company Crotylboration process to produce cryptophycin compounds
CA2467242A1 (en) * 2001-11-20 2003-05-30 Seattle Genetics, Inc. Treatment of immunological disorders using anti-cd30 antibodies
US20040249130A1 (en) * 2002-06-18 2004-12-09 Martin Stanton Aptamer-toxin molecules and methods for using same
ATE499116T1 (de) 2002-08-16 2011-03-15 Immunogen Inc Vernetzer mit hoher reaktivität und löslichkeit und ihre verwendung bei der herstellung von konjugaten für die gezielte abgabe von kleinmolekularen arzneimitteln
US7230101B1 (en) 2002-08-28 2007-06-12 Gpc Biotech, Inc. Synthesis of methotrexate-containing heterodimeric molecules
AU2003285878B2 (en) 2002-11-07 2011-04-28 Immunogen, Inc. Anti-CD33 antibodies and method for treatment of acute myeloid leukemia using the same
EP3851126A1 (en) 2003-05-20 2021-07-21 ImmunoGen, Inc. Maytansinoid-cell-binding agent conjugates
WO2005009369A2 (en) 2003-07-21 2005-02-03 Immunogen, Inc. A ca6 antigen-specific cytotoxic conjugate and methods of using the same
US20050175619A1 (en) 2004-02-05 2005-08-11 Robert Duffy Methods of producing antibody conjugates
EP1718667B1 (en) 2004-02-23 2013-01-09 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
AR048098A1 (es) 2004-03-15 2006-03-29 Wyeth Corp Conjugados de caliqueamicina
AR052774A1 (es) 2004-10-08 2007-04-04 Wyeth Corp Inmunoterapia para trastornos autoinmunes
EP1669358A1 (en) 2004-12-07 2006-06-14 Aventis Pharma S.A. Cytotoxic agents comprising new taxanes
EA013323B1 (ru) * 2004-12-09 2010-04-30 Сентокор, Инк. Иммуноконъюгаты против интегрина, способы и варианты применения
MX2007007590A (es) 2004-12-22 2007-12-10 Ambrx Inc Composiciones que contienen, metodos que involucran y usos de aminoacidos no naturales y polipeptidos.
WO2006096754A2 (en) 2005-03-07 2006-09-14 Archemix Corp. Stabilized aptamers to psma and their use as prostate cancer therapeutics
US7714016B2 (en) 2005-04-08 2010-05-11 Medarex, Inc. Cytotoxic compounds and conjugates with cleavable substrates
PT1813614E (pt) 2006-01-25 2012-01-09 Sanofi Sa Agentes citotóxicos compreendendo novos derivados de tomaimicina
EP1832577A1 (en) 2006-03-07 2007-09-12 Sanofi-Aventis Improved prodrugs of CC-1065 analogs
EP2010475A2 (en) 2006-04-27 2009-01-07 Intezyne Technologies Incorporated Heterofunctional poly(ethylene glycol) containing acid-labile amino protecting groups and uses thereof
EP1864682A1 (en) 2006-06-09 2007-12-12 Sanofi-Aventis Leptomycin derivatives
KR101528939B1 (ko) 2006-07-18 2015-06-15 사노피 암 치료를 위한 ｅｐｈａ2에 대한 길항제 항체
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
WO2009002993A1 (en) * 2007-06-25 2008-12-31 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
SI2019104T1 (sl) 2007-07-19 2013-12-31 Sanofi Citotoksična sredstva, ki obsegajo nove tomaimicinske derivate, in njihova terapevtska uporaba
EP2185188B1 (en) 2007-08-22 2014-08-06 Medarex, L.L.C. Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions
EP2276509B1 (en) 2008-04-11 2016-06-15 Seattle Genetics, Inc. Detection and tratment of pancreatic, ovarian and other cancers
EP2276506A4 (en) 2008-04-30 2014-05-07 Immunogen Inc EFFICIENT CONJUGATES AND HYDROPHILIC BINDER
KR20230003298A (ko) 2008-04-30 2023-01-05 이뮤노젠 아이엔씨 가교제 및 그 용도
WO2010014812A2 (en) 2008-07-30 2010-02-04 The Research Foundation Of State University Of New York Peptide compositions and methods of use

Also Published As

Publication number Publication date
CA2766762C (fr) 2017-06-20
CO6430462A2 (es) 2012-04-30
IL217208A (en) 2016-02-29
ZA201109537B (en) 2013-03-27
SV2011004086A (es) 2012-05-08
SG10201607595WA (en) 2016-11-29
KR20120101981A (ko) 2012-09-17
FR2947269B1 (fr) 2013-01-18
US8952147B2 (en) 2015-02-10
PE20121031A1 (es) 2012-08-17
FR2947269A1 (fr) 2010-12-31
NZ597136A (en) 2014-04-30
JP5746692B2 (ja) 2015-07-08
TW201110986A (en) 2011-04-01
TN2011000636A1 (fr) 2013-05-24
AR078131A1 (es) 2011-10-19
BRPI1015131A2 (pt) 2018-12-04
MA33465B1 (fr) 2012-07-03
EP2448929A1 (fr) 2012-05-09
ECSP11011553A (es) 2012-01-31
HN2011003414A (es) 2014-11-10
CR20110670A (es) 2012-02-09
EA024627B1 (ru) 2016-10-31
JP2012531459A (ja) 2012-12-10
CN102482238B (zh) 2015-08-12
MX2011013764A (es) 2012-05-22
KR101770584B1 (ko) 2017-08-24
EA201270096A1 (ru) 2012-07-30
AU2010267917B2 (en) 2016-03-17
FR2947271B1 (fr) 2013-04-05
WO2011001052A1 (fr) 2011-01-06
US20120225089A1 (en) 2012-09-06
CN102482238A (zh) 2012-05-30
FR2947271A1 (fr) 2010-12-31
DOP2011000376A (es) 2012-01-15
MY156684A (en) 2016-03-15
CA2766762A1 (fr) 2011-01-06
IL217208A0 (en) 2012-03-01
SG177419A1 (en) 2012-02-28
CL2011003229A1 (es) 2012-06-29
NI201100219A (es) 2012-05-23
AU2010267917A1 (en) 2012-02-02

Similar Documents

Publication Publication Date Title
UY32745A (es) Nuevos conjugados de criptoficinas, su preparacion y su aplicacion terapeutica
UY31166A1 (es) Nuevos indazoles sustituidos, su preparación y su utilización en terapeutica
UY33488A (es) Derivados de imidazopiridina, su procedimiento y preparacion y su aplicacion en terapeutica
UY32611A (es) Compuestos de 1-cianoetilheterociclilcarboxamida sustituidos 750
UY35257A (es) Picolinamidas macrocíclicas como fungicidas, composiciones y metodos para el control de enfermedades vegetales
UY31705A1 (es) Derivados de azetidina y ciclobutano como inhibidores de jak
UY31037A1 (es) Derivados de triazolopiridin-carboxamidas, su preparacion y su aplicacion en terapeutica
ECSP11010798A (es) 1,2,5-oxadiazoles como inhibidores de indolamina 2,3-dioxigenasa
CO6650361A2 (es) Derivados de indolizina, su procedimiento de preparacion y su aplicacion en terapeutica
BR112014014809A2 (pt) composições farmacêuticas compreendendo glitazonas e ativadores de nrf2
UY31032A1 (es) Derivados de triazolopiridin-carboxamidas y triazolopirimidin-carboxinamidas, su preparacion y su aplicacion en terapeutica
CR11659A (es) Inhibidores de hsp90
UY31689A1 (es) Derivados de platino-carbeno n-heterocíclico, su preparación y su aplicación en terapéutica
ECSP11011244A (es) Nuevos herbicidas.
UY32553A (es) Nuevos derivados de la pirrolidinadiona espiroheterocíclicos 3-sustituidos
UY30938A1 (es) Derivados de nicotinamida, sales y solvatos farmacéuticamente aceptables, composiciones y aplicaciones.
CU20110220A7 (es) Espiro-epóxidos como productos intermedios
UY33415A (es) Composiciones de alcoxicarboxamidas microbiocidas y fungicidas y su preparacion
CO6511204A2 (es) Derivados de isoxazolidina
CO6341625A2 (es) Derivados de indol como agentes anticáncer
ECSP11011217A (es) Microbiocidas nuevos.
UY30865A1 (es) Nuevos analogos de piridina x 161
UY30729A1 (es) Derivados de pirrol, su preparacion y su utilizacion en terapéutica
UY30867A1 (es) Nuevos analogos de piridina vii 543
BR112012008952A2 (pt) microbicidas

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20190207